Abstract
This University of Central Florida invention introduces a skin patch composed of
dissolvable silk fibroin microneedles designed to deliver thyroid hormone
(levothyroxine) over extended periods. The patch provides a non-invasive
alternative to daily oral medication, improving patient compliance and
bypassing gastrointestinal absorption issues. Two versions of the patch are
under development, offering hormone release durations of approximately 8 and 20
months respectively. The technology is applicable to other drugs requiring
long-term delivery and has potential for broad therapeutic use.
Technical Details: The patch consists of an array of microneedles fabricated
from silk fibroin, a biocompatible and biodegradable protein. These
microneedles penetrate the outer layer of the skin and dissolve gradually,
releasing the encapsulated hormone into the bloodstream. The release rate is
controlled by the formulation and structure of the silk matrix. The patch is
designed for single application and sustained release, reducing the frequency
of dosing and improving treatment outcomes.
Benefit
Improved Patient Compliance: Reduces reliance on daily medication intake.Long-Term Delivery: Provides hormone release for up to 20 months.Minimized Side Effects: Avoids gastrointestinal absorption variability.Painless Application: Microneedles are minimally invasive and dissolve naturally.Market Application
Thyroid Disorder Treatment: Long-term levothyroxine delivery for hypothyroidism patients.Drug Delivery Platforms: Adaptable for antibiotics and other chronic medications. Remote Healthcare: Useful in settings with limited access to regular medical care.Veterinary Medicine: Potential for long-term treatment in animals.
Brochure
